Restricted accessResearch articleFirst published online 2017-3-21
Targeted Metabolomic Analysis of Soluble Lysates from Platelets of Patients with Mild Cognitive Impairment and Alzheimer’s Disease Compared to Healthy Controls: Is PC aeC40:4 a Promising Diagnostic Tool?
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of the central nervous system. The use of biological fluids in AD diagnosis remains limited to the analysis of specific protein biomarkers in cerebrospinal fluid. However, metabolomic analysis has recently revealed several metabolites in plasma, especially phosphatidylcholines (PC), as putative biomarkers specific for AD. Following on previous reports of platelet abnormalities in AD, we hypothesized that platelets metabolites released in plasma may offer new biomarkers in AD. The aim of the present study was to apply targeted metabolomics to compare metabolites in soluble lysates of platelets from healthy controls (CO), patients with mild cognitive impairment (MCI), and patients with AD in a cohort of 90 subjects. We could target 163 metabolites and quantitative data were obtained for 91 metabolites. Among these, the lipid PC aeC40:4 significantly differentiated AD from CO (p = 0.0009), while four other lipids (PC aaC32:0, PC ae C32:2, PC aeC34:1, and SM(OH)C14:1) differentiated patients with MCI from CO. The combination of three phosphatidylcholines (PC aeC32:2, PC aeC34:1, PCaaC36:5), two lyso-phosphatidylcholines (lysoPC aC18:1, lysoPC aC16:0), and one sphingomyelin (SM(OH) C14:1) constructed a valuable prediction model using the C4.5 decision tree. The diagnosis accuracy for AD versus CO and MCI was 85%. In a blinded follow up conversion study (10 patients with a second blood collection after 9 months), we could verify the clinical diagnosis in 19 out of 20 cases. We propose that soluble platelet PCaeC40:4 is a promising marker to diagnose AD with a cut-off of <0.30μM and that platelets undergo metabolic processes during AD progression.
LiQX, FullerSJ, BeyreutherK, MastersCL (1999) The amyloid precursor protein of Alzheimer disease in human brain and blood. J Leukoc Biol66, 567–574.
8.
PadovaniA, PastorinoL, BorroniB, ColciaghiF, RozziniL, MonasteroR, PerezJ, PettenatiC, MussiM, ParrinelloG, CottiniE, LenziGL, TrabucchiM, CattabeniF, Di LucaM (2001) Amyloid precursor protein in platelets: A peripheral marker for the diagnosis of sporadic AD. Neurology57, 2243–2248.
9.
Di LucaM, PastorinoL, CattabeniF, ZanardiR, ScaroneS, RacagniG, SmeraldiE, PerezJ (1996) Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Arch Neurol53, 1162–1166.
10.
BorroniB, ColciaghiF, ArchettiS, MarcelloE, CaimiL, Di LucaM, PadovaniA (2004) Predicting cognitive decline in Alzheimer disease. Role of platelet amyloid precursor protein. Alzheimer Dis Assoc Dis18, 32–34.
11.
NeumannK, FaríasG, SlachevskyA, PerezP, MaccioniRB (2011) Human platelets tau: A potential peripheral marker for Alzheimer’s disease. J Alzheimers Dis25, 103–109.
12.
HochstrasserT, EhrlichD, MarksteinerJ, Sperner-UnterwegerB, HumpelC (2012) Matrix metalloproteinase-2 and epidermal growth factor are decreased in platelets of Alzheimer patients. Curr Alzheimer Res9, 982–989.
13.
MarksteinerJ, HumpelC (2013) Platelet-derived secreted amyloid-precursor protein-β as a marker for diagnosing Alzheimer’s disease. Curr Neurovasc Res10, 297–230.
14.
VeitingerM, OehlerR, UmlaufE, BaumgartnerR, SchmidtG, GernerC, BabelukR, AttemsJ, MitulovicG, RappoldE, LamontJ, ZellnerM (2014) A platelet protein biochip rapidly detects an Alzheimer’s disease-specific phenotype. Acta Neuropathol128, 665–677.
15.
JarreA, GowertNS, DonnerL, MünzerP, KlierM, BorstO, SchallerM, LangF, KorthC, ElversM (2014) Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer’s disease. Cell Signal26, 2040–2050.
16.
GowertNS, DonnerL, ChatterjeeM, EiseleYS, TowhidST, MünzerP, WalkerB, OgorekI, BorstO, GrandochM, SchallerM, FischerJW, GawazM, WeggenS, LangF, JuckerM, ElversM (2014) Blood platelets in the progression of Alzheimer’s disease. PLoS One9, e90523.
17.
BjörkqvistM, OhlssonM, MinthonL, HanssonO (2012) Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer’s disease. PLoS One7, e29868.
FarooquiAA, HorrocksLA, FarooquiT (2000) Glycerophospholipids in brain: Their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem Phys Lipids106, 1–29.
20.
FrisardiV, PanzaF, SeripaD, FarooquiT, FarooquiAA (2011) Glycerophospholipids and glycerophospholipid-derived lipid mediators: A complex meshwork in Alzheimer’s disease pathology. Prog Lipid Res50, 313–330.
21.
HaugheyNJ, BandaruVV, BaeM, MattsonMP (2010) Roles for dysfunctional sphingolipid metabolism in Alzheimer’s disease neuropathogenesis. Biochim Biophys Acta1801, 878–886.
AhmadW (2013) Overlapped metabolic and therapeutic links between Alzheimer and diabetes. Mol Neurobiol47, 399–424.
24.
ProitsiP, KimM, WhileyL, PritchardM, LeungR, SoininenH, KloszewskaI, MecocciP, TsolakiM, VellasB, ShamP, LovestoneS, PowellJF, DobsonRJ, Legido-QuigleyC (2015) Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer’s disease. Transl Psychiatry5, e494.
25.
WoodPL (2014) Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology. Neuropsychopharmacology39, 24–33.
OlazaranJ, Gil-deGomezL, Rodriguez-MartinA, Valenti-SolerM, Frades-PayoB, Marin-MunozJ, AntunezC, Frank-GarciaA, JimenezCA, GraviaLM, TorregrossaRP, GuisasolaMC, Bermejo-ParaejaF, Sanchez-FerroA, Perez-MartinezDA, PalomoSM, FarquharR, RabanoA, CaleroM (2015) A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer’s disease. J Alzheimers Dis45, 1157–1173.
28.
FiandacaMS, ZhongX, CheemaAK, OrquizaMH, ChidambaramS, TanMT, GresenzCR, FitzGeraldKT, NallsMA, SingletonAB, MapstoneM, FederoffHJ (2015) Plasma 24-metabolite panel predicts preclinical transition to clinical stages of Alzheimer’s disease. Front Neurol6, 237.
29.
KlavinsK, KoalT, DallmannG, MarksteinerJ, KemmlerG, HumpelC (2015) The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer’s disease and mild cognitive impairment. Alzheimers Dement (Amst)1, 295–302.
30.
PetersenRC, DoodyR, KurzA, MohsRC, MorrisJC, RabinsPV, RitchieK, RossorM, ThalL, WinbladB (2001) Current concepts in mild cognitive impairment. Arch Neurol58, 1985–1992.
31.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology34, 939–944.
32.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
33.
WelshKA, ButtersN, MohsRC, BeeklyD, EdlandS, FillenbaumG, HeymanA (1994) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology44, 609–614.
34.
ScheltensP, LeysD, BarkhofF, HugloD, WeinsteinHC, VermerschP, KuiperM, SteinlingM, WoltersEC, ValkJ (1992) Atrophy of medial temporal lobes on MRI in probable Alzheimers disease and normal aging— diagnostic-value and neuropsychological correlates. J Neurol Neurosurg Psychiatry55, 967–972.
35.
Core R Team (2015) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/
O’DonnellVB, MurphyRC, WatsonSP (2014) Platelet lipidomics: Modern day perspective on lipid discovery and characterization in platelets. Circ Res114, 1185–1203.
46.
HeX, HuangY, LiB, GongCX, SchuchmanEH (2010) Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiol Aging31, 398–408.
47.
HanX, RozenS, HellegersC, ChengH, BurkeJR, Welsh-BohmerKA, DoraiswamyPM, Kaddurah-DaoukR (2014) Metabolomics in early Alzheimer’s disease: Identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One6, e21643.
48.
MielkeMM, LyketsosCG (2010) Alterations of the sphingolipid pathway in Alzheimer’s disease: New biomarkers and treatment targets?Neuromolecular Med12, 331–340.
49.
KatselP, LiC, HaroutunianV (2007) Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: A shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease?Neurochem Res32, 845–856.
50.
KoalT, KlavinsK, SeppiD, KemmlerG, HumpelC (2015) Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples. J Alzheimers Dis44, 1193–1201.
51.
SprottRL (2010) Biomarkers of aging and disease: Introduction and definitions. Exp Gerontol45, 2–4.
52.
PagliaG, SigurjónssonÓE, RolfssonÓ, HansenMB, BrynjólfssonS, GudmundssonS, PalssonBO (2015) Metabolomic analysis of platelets during storage: A comparison between apheresis- and buffy coat-derived platelet concentrates. Transfusion55, 301–313.
53.
JuHK, LeeJG, ParkMK, ParkSJ, LeeCH, ParkJH, KwonSW (2012) Metabolomic investigation of the anti-platelet aggregation activity of ginsenoside Rk1 reveals attenuated 12-HETE production. J Proteome Res11, 4939–4946.
